Deerfield Management VYGR Position
ExitedDeerfield Management exited their position in Voyager Therapeutics Inc. (VYGR) in Q2 2024, after holding the stock for 3 quarters.
The position was first reported in Q4 2023 and has been tracked across 3 quarterly 13F filings.
2 other tracked funds also hold VYGR.
There is an upcoming Phase 2 readout for VY7523 in 410 days (May 31, 2027), making the timing of Deerfield's position particularly relevant.
About Voyager Therapeutics Inc.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
6.3%
3.7 days to cover
Deerfield Management VYGR Position History
Frequently Asked Questions
Does Deerfield Management own VYGR?
No. Deerfield Management exited their position in Voyager Therapeutics Inc. (VYGR) in Q2 2024. They previously held the stock for 3 quarters.
How many hedge funds own VYGR?
2 specialist biotech hedge funds currently hold VYGR, including EcoR1 Capital, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy VYGR?
Deerfield Management's position in VYGR was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's VYGR position increasing or decreasing?
Deerfield Management completely exited their VYGR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VYGRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →